基于PBPK模型评估曲奥舒凡的药物相互作用潜力
本研究通过建立曲奥舒凡的生理药动学(PBPK)模型,以咪达唑仑、奥美拉唑和地高辛为探针,评估其对CYP3A4、CYP2C19和P-gp的DDI潜力。结果显示曲奥舒凡对CYP3A4和CYP2C19分别为中、低潜力抑制(AUCRmax=2.23和1.6),对P-gp无抑制;若在输注前后特定时间给药,所有机制交互潜力低(AUCR<1.25)。
要点
- 曲奥舒凡对CYP3A4有中等抑制潜力,AUCRmax为2.23
- 曲奥舒凡对CYP2C19有低抑制潜力,AUCRmax为1.6
- 曲奥舒凡不预测引起P-gp介导的DDI
核心结论
- 曲奥舒凡治疗期间不应合用CYP3A4、CYP2C19或P-gp底物的窄治疗指数药物(如地高辛)。
- 若合用药在曲奥舒凡2小时静脉输注前2小时或后8小时给药,所有评估机制的相互作用潜力低(AUCR<1.25)。
研究设计与样本
- 基于文献和未发表临床数据从头建立曲奥舒凡PBPK模型,并进行DDI分析,采用FDA DDI指数药物咪达唑仑、奥美拉唑和地高辛作为CYP3A4、CYP2C19和P-gp的探针底物。
主要发现
- 曲奥舒凡PBPK模型能预测标准预处理方案下曲奥舒凡的血浆浓度-时间曲线和暴露水平。
- 预测曲奥舒凡对CYP3A4有中等DDI潜力,AUCRmax=2.23。
- 预测曲奥舒凡对CYP2C19有低DDI潜力,AUCRmax=1.6。
- 预测曲奥舒凡不引起P-gp介导的DDI。
关键数值与推荐
- CYP3A4探针咪达唑仑的AUCRmax=2.23。
- CYP2C19探针奥美拉唑的AUCRmax=1.6。
- 联合用药在曲奥舒凡输注前2小时或后8小时给药时,所有评估机制的AUCR<1.25。
临床怎么用
- 避免在曲奥舒凡治疗期间合用CYP3A4、CYP2C19或P-gp底物的窄治疗指数药物(如地高辛)。
- 合用药可在曲奥舒凡2小时静脉输注前2小时或后8小时给药以降低相互作用风险。
局限性
- 模型基于文献和未发表数据,预测需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this work is the development of a mechanistic physiologically-based pharmacokinetic (PBPK) model using in vitro to in vivo extrapolation to conduct a drug-drug interaction (DDI) assessment of treosulfan against two cytochrome p450 (CYP) isoenzymes and P-glycoprotein (P-gp) substrates. METHODS: A PBPK model for treosulfan was developed de novo based on literature and unpublished clinical data. The PBPK DDI analysis was conducted using the U.S. Food and Drug Administration (FDA) DDI index drugs (probe substrates) midazolam, omeprazole and digoxin for CYP3A4, CYP2C19 and P-gp, respectively. Qualified and documented PBPK models of the probe substrates have been adopted from an open-source online model database. RESULTS: The PBPK model for treosulfan, based on both in vitro and in vivo data, was able to predict the plasma concentration-time profiles and exposure levels of treosulfan applied for a standard conditioning treatment. Medium and low potentials for DDI on CYP3A4 (maximum area under the concentration-time curve ratio (AUCRmax = 2.23) and CYP2C19 (AUCRmax = 1.6) were predicted, respectively, using probe substrates midazolam and omeprazole. Treosulfan was not predicted to cause a DDI on P-gp. CONCLUSION: Medicinal products with a narrow therapeutic index (eg, digoxin) that are substrates for CYP3A4, CYP2C19 or P-gp should not be given during treatment with treosulfan. However, considering the comprehensive treosulfan-based conditioning treatment schedule and the respective pharmacokinetic properties of the concomitantly used drugs (eg, half-life), the potential for interaction on all evaluated mechanisms would be low (AUCR < 1.25), if concomitantly administered drugs are dosed either 2 hours before or 8 hours after the 2-hour intravenous infusion of treosulfan.
引用
- Schaller S, Martins FS, Balazki P, et al. Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach. Br J Clin Pharmacol. 2021. PMID: 34519068. doi:10.1111/bcp.15081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。